TICKERNERD
Menu
ADCTADCTHealthcare · Drug Manufacturers - Specialty & Generic

ADCT Stock Forecast: ADC Therapeutics SA Price Predictions for 2026-2027

Last close, 21 Aug 2026
$0.99
+3.57% on the day

The 5 Wall Street analysts covering ADC Therapeutics SA hold a median 12-month price target of $3 — +201.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 73 of 100 as at 22 Aug 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$127.0M
Ticker Nerd rank
73 / 100
Median analyst target
$3.00
Analysts covering
5
Total return, dividends reinvested
1W
−1.5%
1M
−21.7%
YTD
−71.8%
1Y
−67.9%
From 52W high
−79.6%
From 52W low
+3.6%
$0.96
$4.88
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ADCT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores ADC Therapeutics SA on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
73 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
93
Revisions
76
Issuance
75
Size
73
Quality
71
Accruals
67
Value
36
Volatility
15
Momentum
10

Growth (93): Sales and profits are climbing, and climbing faster than before.

Momentum (10): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ADCT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ADCT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00Oct 25Jan 26Apr 26Jul 26ADCTHigh $5.00Median $3.00Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts
3 Buy2 Hold0 Sell
Low $2.00Median $3.00High $5.00

The green dot is the last close — the median target sits +201.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Aug 2026GuggenheimMaintainsBuy$10 → $5.00
8 June 2026HC Wainwright & Co.DowngradeNeutral—
8 June 2026HC Wainwright & Co.DowngradeNeutral—
4 June 2026RBC CapitalDowngradeSector Perform—
4 June 2026RBC CapitalDowngradeSector Perform$6.00 → $2.00
5 May 2026HC Wainwright & Co.ReiteratesBuy—
5 May 2026RBC CapitalReiteratesOutperform—
23 Mar 2026HC Wainwright & Co.MaintainsBuy—
16 Oct 2025HC Wainwright & Co.MaintainsBuy—
13 Aug 2025GuggenheimReiteratesBuy—
20 June 2025RBC CapitalMaintainsOutperform—
13 June 2025GuggenheimMaintainsBuy—
15 May 2025RBC CapitalReiteratesOutperform—
31 Mar 2025GuggenheimMaintainsBuy—
31 Mar 2025HC Wainwright & Co.ReiteratesBuy—
7 Mar 2025Cantor FitzgeraldReiteratesOverweight—
24 Feb 2025Stephens & Co.MaintainsOverweight—
6 Jan 2025HC Wainwright & Co.ReiteratesBuy—
12 Dec 2024GuggenheimReiteratesBuy—
11 Dec 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ADCT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ADCT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

ADC Therapeutics SA (ADCT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.9×

Cheaper than 82% of US stocks

Price / sales
1.6×

Cheaper than 59% of US stocks

Price / book
−0.7×

Cheaper than 94% of US stocks

EV / EBITDA
−3.6×

Cheaper than 76% of US stocks

Growth & margins
Revenue growth (YoY)
2.2%

Higher than 32% of US stocks

Earnings growth (YoY)
−9.5%

Higher than 26% of US stocks

Gross margin
82.7%

Higher than 92% of US stocks

Operating margin
−118.1%

Higher than 13% of US stocks

Net margin
−121.8%

Higher than 5% of US stocks

Returns & dividend
Return on equity
76.7%

Higher than 95% of US stocks

Return on assets
−19.6%

Higher than 20% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ADCT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
ADCTADC Therapeutics SA$127.0M
73
CPIXCumberland Pharmaceuticals, Inc.$114.6M
85
BGMBGM Group Ltd.$110.3M
33
LFCRLifecore Biomedical, Inc.$170.1M
4
OGIOrganigram Global, Inc.$177.3M
40
DERMJourney Medical Corp.$211.8M
67
CRDLCardiol Therapeutics, Inc.$217.4M
62

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own ADC Therapeutics SA — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ADCT news & analysis

ADC Therapeutics Q2 Earnings Call Highlights

MarketBeat · 13 Aug 2026neutral

ADC Therapeutics reported second-quarter 2026 net product revenue of $18.6 million for ZYNLONTA, up from $18.1 million in the prior-year period, with management saying the treatment's commercial performance remained broadly consistent with recent quarters during the Q2 earnings call.

Why it matters — The quarter-over-quarter growth and management's assessment of ZYNLONTA's commercial performance provide a point of reference for investors tracking ADC Therapeutics' revenue trajectory.

ADC Therapeutics SA (ADCT) Q2 2026 Earnings Call Transcript

Seeking Alpha · 13 Aug 2026neutral

ADC Therapeutics SA held its Q2 2026 earnings call, with the transcript published by Seeking Alpha. The call covered the company's financial results and operational updates for the quarter.

Why it matters — Earnings calls provide ADCT watchers with direct management commentary on the company's financial performance and strategic direction.

ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research · 13 Aug 2026positive

ADC Therapeutics reported a Q2 loss of $0.11 per share, narrower than the Zacks Consensus Estimate of a $0.19 loss and improved from the $0.50 per-share loss a year earlier. Revenue lagged consensus estimates for the quarter.

Why it matters — The narrower-than-expected quarterly loss marks an improvement from the prior year, though the revenue shortfall signals ADCT still faces demand headwinds.

ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates

PRNewsWire · 13 Aug 2026neutral

ADC Therapeutics reported second quarter 2026 financial results with $18.6 million in net product revenue and $219.1 million in cash. The company also provided operational updates, including data submissions for ASH and a regulatory evaluation for ZYNLONTA® to pursue full approval and earlier-line DLBCL treatment.

Why it matters — ADCT watchers would care because the company is advancing ZYNLONTA® toward full approval and earlier lines of treatment for DLBCL, which could significantly expand its commercial opportunity.

ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026

PRNewsWire · 6 Aug 2026neutral

ADC Therapeutics SA (NYSE: ADCT) announced it will host a conference call and live webcast on Thursday, August 13, 2026, at 8:30 a.m. EDT to report its financial results for the second quarter of 2026 and provide operational updates. The announcement was made from Lausanne, Switzerland.

Why it matters — The event will give ADCT watchers the company's official second-quarter 2026 financial results and operational updates.

FAQ

Frequently asked questions about ADCT stock

What is the ADCT stock price forecast for 2026-2027?

The 5 Wall Street analysts covering ADC Therapeutics SA have a median 12-month price target of $3, with estimates ranging from $2 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ADCT stock a buy right now?

Of the 5 analysts covering ADC Therapeutics SA, 3 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ADC Therapeutics SA 73 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ADCT?

As at 22 Aug 2026, ADC Therapeutics SA ranks 73 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (93 of 100).

Will ADCT stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +201.7% from the last close, and Ticker Nerd's factor model ranks ADC Therapeutics SA 73 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ADCT stock forecast for 2030?

No analyst covering ADC Therapeutics SA publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ADCT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $5 over the next 12 months.

How has ADCT stock performed over the past year?

ADC Therapeutics SA returned -67.9% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does ADC Therapeutics SA do?

ADC Therapeutics S.A. is a biotechnology company engaged in developing and commercializing antibody-drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors.

What is the latest news on ADCT?

The most recent item we track (MarketBeat, 13 Aug 2026): "ADC Therapeutics Q2 Earnings Call Highlights". ADC Therapeutics reported second-quarter 2026 net product revenue of $18.6 million for ZYNLONTA, up from $18.1 million in the prior-year period, with management saying the treatment's commercial performance remained broadly consistent with recent quarters during the Q2 earnings call.

Company

About ADC Therapeutics SA.

ADC Therapeutics S.A. is a biotechnology company engaged in developing and commercializing antibody-drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. The primary goal of ADC Therapeutics is to address major unmet medical needs by harnessing the potency of targeted drug delivery. By combining the targeting capability of monoclonal antibodies with the cancer-killing effects of potent cytotoxic drugs, the company's ADCs aim to selectively attack cancer cells while minimizing damage to healthy tissues. ADC Therapeutics targets a range of malignancies, including non-Hodgkin lymphoma and other aggressive blood cancers, with a robust pipeline of therapeutics in various stages of clinical trials. Headquartered in Switzerland, the company plays a significant role in the biopharmaceutical industry, collaborating with other research entities and leveraging cutting-edge technology to advance cancer treatment. Its scientific innovation and potential breakthrough therapies contribute substantially to the evolving landscape of oncology medicine.

CEO Dr. Ameet Mallik M.B.A., M.S. · 188 employees · Switzerland · https://www.adctherapeutics.com